| Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis |
Globe Newswire |
06/22 |
08:30 |
| NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization |
Globe Newswire |
06/22 |
08:30 |
| Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity |
Globe Newswire |
06/22 |
08:30 |
| Atlantic International Reports Record First Quarter 2026 Revenue of $249.9 Million |
Globe Newswire |
06/22 |
08:27 |
| Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery |
Globe Newswire |
06/22 |
08:22 |
| GRAL INVESTOR NOTICE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law |
Globe Newswire |
06/22 |
08:15 |
| Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial |
Globe Newswire |
06/22 |
08:07 |
| Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts |
Globe Newswire |
06/22 |
08:05 |
| Outdoor Holding Company Reports Fourth Quarter and Fiscal Year 2026 Financial Results |
Globe Newswire |
06/22 |
08:05 |
| LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection |
Globe Newswire |
06/22 |
08:00 |
| Atsena Therapeutics Doses First Patient and Reports Rapid Early Enrollment in Pivotal Trial of ATSN-201 for X-Linked Retinoschisis |
Globe Newswire |
06/22 |
08:00 |
| Tyson® Debuts New Garlic & Herb, BBQ, and Harissa Chicken Cups |
Globe Newswire |
06/22 |
08:00 |
| Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition |
Globe Newswire |
06/22 |
08:00 |
| Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D. |
Globe Newswire |
06/22 |
08:00 |
| Medidata Unveils New Academic Board to Bridge the Gap Between Research and Patient Care |
Globe Newswire |
06/22 |
08:00 |
| Skyborne Technology, Inc (STI), a UAV Corp Company, completes initial step for Weight Balance Analysis and Flight Testing |
Globe Newswire |
06/22 |
08:00 |
| Kandi Technologies Accelerates Global Expansion |
Globe Newswire |
06/22 |
08:00 |
| NorthStar Secures Over CAD$40M with 3 Canadian Space Division to Advance Sovereign Space Domain Awareness |
Globe Newswire |
06/22 |
08:00 |
| Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) |
Globe Newswire |
06/22 |
08:00 |
| ASML reports transactions under its current share buyback program |
Globe Newswire |
06/22 |
08:00 |
| EagleNXT Secures Order of eBee VISION ISR and eBee TAC Systems from Asia Pacific Customer |
Globe Newswire |
06/22 |
08:00 |
| Westport Announces US$10 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules |
Globe Newswire |
06/22 |
08:00 |
| Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants |
Globe Newswire |
06/22 |
08:00 |
| NordLayer Named a Winner in the Expert Insights Cybersecurity Awards Summer 2026 for Network Security |
Globe Newswire |
06/22 |
08:00 |
| Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis, and Last Patient, Last Visit in an Investigator-Led Study of PRO-203 in Refractory Lupus Nephritis |
Globe Newswire |
06/22 |
08:00 |
